Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting

BACKGROUND: A regimen of dual (DAT) vs. triple (TAT) antithrombotic therapy reduces bleeding in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, recent evidence suggests that DAT may be associated with an increased ischemic risk. This raises the qu...

Fuld beskrivelse

Bibliografiske detaljer

Udgivet i:	Int J Cardiol Heart Vasc
Main Authors:	Riesinger, Lisa, Strobl, Claudia, Leistner, David M., Gori, Tommaso, Akin, Ibrahim, Mehr, Michael, Kellnar, Antonia, Mahabadi, Amir A., Bogossian, Harilaos, Block, Michael, Edelmann, Frank, Sarafoff, Nikolaus, Sibbing, Dirk, Ince, Hüseyin, Rassaf, Tienush, Mansmann, Ulrich, Mehilli, Julinda, Kääb, Stefan, Hausleiter, Jörg, Massberg, Steffen, Wakili, Reza
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2021
Fag:	Original Paper
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC8256176/ https://ncbi.nlm.nih.gov/pubmed/34258380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijcha.2021.100810
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!